Press Releases

GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer

LEXINGTON, Massachusetts & SYDNEY – April 30, 2013 – GI Dynamics, Inc. (ASX: GID) today announced the appointment of David Maggs, M.D. to the position of chief medical officer. In this role, Dr. Maggs will oversee clinical development and medical affairs for the Company’s lead...

read more

GI Dynamics, Inc. Reports on Progress of the ENDO Trial

LEXINGTON, Massachusetts & SYDNEY, Australia – 25 April 2013 – GI Dynamics, Inc. (ASX: GID) today announced an update on the status of the ENDO Trial, its U.S. multi-center, pivotal clinical trial of EndoBarrier® for the treatment of patients who have uncontrolled type 2 diabetes and are...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more

GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier® Therapy in Brazil

ANVISA Regulatory Submission Filed LEXINGTON, Massachusetts, SYDNEY, Australia & GOIÂNIA, Brazil – 6 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that it has entered into an agreement with CMS Medical (CMS), headquartered in Goiânia, Brazil, to distribute its lead product,...

read more

GI Dynamics to Present at the Cowen & Co. 33rd Annual Healthcare Conference

LEXINGTON, Massachusetts and SYDNEY – 26 February 2013 – GI Dynamics, Inc. (ASX: GID), a company pioneering the development of effective, non-surgical approaches for treating type 2 diabetes and obesity, announced today that Stuart A. Randle, president and chief executive officer, will present an...

read more

GI Dynamics Announces Commercial Availability of EndoBarrier® Therapy in Israel for the Treatment of Type 2 Diabetes and/or Obesity

Sheba Medical Center is First to Offer EndoBarrier Therapy in Israel LEXINGTON, Massachusetts & SYDNEY – 26 February 2013 – GI Dynamics, Inc. (ASX: GID) today announced that The Sheba Medical Center (Tel Hashomer) at Ramat-Gan, Israel, is now offering EndoBarrier® Therapy, a non-surgical,...

read more

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for 2012

LEXINGTON, Mass. and SYDNEY – 19 February 2013 – GI Dynamics, Inc. (ASX: GID) will hold a conference call to discuss the Company’s financial results for the year ended December 31, 2012, and its business outlook. Stuart A. Randle, president and chief executive officer, will host the call with...

read more

Data Show EndoBarrier® Therapy Demonstrates Glycemic Control in People with Type 2 Diabetes Who are Mildly Obese

 — Results Published in Journal of Clinical Endocrinology & Metabolism Show EndoBarrier Effects in People with Type 2 Diabetes and Lower Body Mass Index —  LEXINGTON, Massachusetts & SYDNEY – January 31, 2013 — GI Dynamics, Inc. (ASX: GID) today announced the publication...

read more

GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier®

LEXINGTON, Mass. & SYDNEY — Jan. 15, 2013 — GI Dynamics, Inc. (ASX: GID) today announced that it has initiated its U.S. multicenter pivotal clinical trial of EndoBarrier®, the ENDO Trial, for the treatment of patients who have uncontrolled type 2 diabetes and are obese. EndoBarrier...

read more
Page 10 of 17« First...89101112...Last »